新辅助化疗对晚期上皮性卵巢癌免疫微环境的影响研究进展  

作　　者：董绍华[1] 田翔宇 崔秀娟[1] 王稳[1] 

机构地区：[1]滕州市中心人民医院妇产科,277599 [2]滕州市中心人民医院医学影像中心,277599

出　　处：《妇产与遗传（电子版）》2020年第3期56-61,共6页Obstetrics-Gynecology and Genetics (Electronic Edition)

基　　金：山东省医药卫生科技发展计划项目(2018WSA04019);济宁医学院教师科研扶持基金(JYFC2019FKJ057)。

摘　　要：在过去的数十年里,越来越多的证据证实了宿主免疫系统在控制肿瘤生长方面起着重要作用,肿瘤浸润淋巴细胞与提高上皮性卵巢癌患者的生存率密切相关。然而,仅有少数研究关注新辅助化疗(neoadjuvant chemotherapy,NACT)对肿瘤免疫微环境的影响。本文将对肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TILs)亚群在卵巢癌中的预后价值,新辅助化疗对TILSs的影响以及与晚期卵巢癌临床预后的关系等最新研究进展进行综述,以期为将来免疫治疗作为初始治疗后的维持治疗提供参考。Over the last decades,increasing evidence highlights the role of the host immune system in the control of tumor growth and the prognostic implications of tumor infiltrating lymphocytes(TILs)in ovarian cancer.However,only a small number of studies have focused on the effect of neoadjuvant chemotherapy(NACT)on the tumor immune microenvironment.This review will provide an update on the prognostic value of TILs subpopulations on ovarian cancer,a comprehensive overview of the recent studies evaluating the impact of NACT on TILs and their relationship to clinical outcome in advanced ovarian cancer,which is expected to provide reference for future immunotherapy as maintenance following primary treatment.

关 键 词：免疫微环境 新辅助化疗 上皮性卵巢癌 

分 类 号：R737.3[医药卫生—肿瘤]